Quest Diagnostics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DGX and other ETFs, options, and stocks.

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments.

CEO

James E. Davis

CEOJames E. Davis

Employees

56,000

Employees56,000

Headquarters

Secaucus, New Jersey

HeadquartersSecaucus, New Jersey

Founded

1967

Founded1967

Employees

56,000

Employees56,000

DGX Key Statistics

Market cap

22.74B

Market cap22.74B

Price-Earnings ratio

23.48

Price-Earnings ratio23.48

Dividend yield

1.56%

Dividend yield1.56%

Average volume

1.46M

Average volume1.46M

High today

—

High today—

Low today

—

Low today—

Open price

$205.56

Open price$205.56

Volume

0.00

Volume0.00

52 Week high

$213.20

52 Week high$213.20

52 Week low

$157.20

52 Week low$157.20

Stock Snapshot

With a market cap of 22.74B, Quest Diagnostics(DGX) trades at $204.39. The stock has a price-to-earnings ratio of 23.48 and currently yields dividends of 1.6%.

On 2026-02-19, Quest Diagnostics(DGX) shares started trading at $205.56, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.46M.

Over the past 52 weeks, Quest Diagnostics(DGX) stock has traded between a high of $213.20 and a low of $157.20.

DGX News

Simply Wall St 2d

Evaluating Quest Diagnostics After Dividend Hike Strong Earnings Guidance And Expanded Buyback

Quest Diagnostics (DGX) is back in focus after a busy February 10 update, combining higher quarterly and full year 2025 earnings, fresh 2026 guidance, a 7.5% di...

Simply Wall St 4d

Quest Diagnostics Is Up 8.5% After Strong 2026 Guidance And New Myeloma Test Launch - Has The Bull Case Changed?

In February 2026, Quest Diagnostics reported Q4 and full-year 2025 results with higher sales and earnings, issued 2026 guidance calling for US$11.70–US$11.82 bi...

Simply Wall St 7d

Quest Diagnostics MRD Blood Test May Support Growth In Higher Value Oncology

Quest Diagnostics (NYSE:DGX) has introduced a blood based minimal residual disease test for multiple myeloma that uses advanced flow cytometry. The company rep...

Analyst ratings

52%

of 21 ratings

Buy

42.9%

Hold

52.4%

Sell

4.8%

More DGX News

TipRanks 7d

Quest Diagnostics price target raised to $235 from $210 at Mizuho

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $235 from $210 and keeps an Outperform rating on the shares. Published first on TheFly – th...

People also own

Based on the portfolios of people who own DGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.